Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Epigenetic and Genetic interplay in Liver Cancer

Project description

Understanding liver cancer tumour development

Liver cancer represents a leading cause of mortality, yet little is known about its cellular origins. While the genetic triggers for liver cancer are well documented, the ways in which cancer-driver mutations and epigenetic erosion collaborate to promote cellular plasticity remain unexplored. Supported by the Marie Skłodowska-Curie Actions programme, the EpiGen-LC project will address this knowledge gap, aiming to identify foundational risk factors of liver cancer to guide the development of improved early detection strategies. Leveraging CRISPR techniques, it will insert cancer-driver mutations in organoids from healthy and damaged liver tissue to analyse how liver cancer-driver mutations promote epigenetic remodelling and cellular plasticity as well as how such epigenetic changes further amplify cancer-promoting activity.

Objective

Liver cancer is a leading cause of mortality worldwide, yet its cellular origins are poorly understood. The Valier lab (host) has shown that a population of hepatocyte-cholangiocyte bi-phenotypic cells expands during the progression of chronic liver disease (MASLD). Chronic injury leads to epigenetic erosion, which has been recognised as a cancer hallmark. Whilst genetic drivers of liver cancer have been identified, the capacity of epigenetic erosion and cancer-driver mutations to cooperate to drive cellular plasticity has not been explored. This fellowship will build on my expertise in somatic mutation acquisition in chronically inflamed tissues to: O1. Determine the capacity of liver cancer-driver mutations to promote epigenetic remodelling and cellular plasticity, and O2. Determine the capacity of epigenetic remodelling to drive cellular plasticity and enhance the function of liver cancer-driver mutations. The Vallier lab is uniquely positioned to host this project, having established protocols to derive and transdifferentiate human cholangiocyte and hepatocyte organoids. Using CRISPR, I will introduce cancer-driver mutations in organoids from healthy and epigenetically eroded end-stage liver disease tissue and evaluate the impact on plasticity between hepatocytes and cholangiocytes. This fellowship will give me expertise in liver biology, patient-derived organoids, genome engineering, epigenomic profiling, as well as bioinformatic skills. Communication and outreach will be supported by the international and translational environment of the BIH at Charité and the MPI-MG. I will acquire an interdisciplinary collaborative network and develop leadership skills under the mentorship of Prof. Dr. Vallier. By combining access to rare liver organoids with my background in mutation dynamics, the project will uncover early determinants of liver cancer that may inform strategies for early detection, and equip me to transition into an independent academic research career.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Net EU contribution
€ 202 125,12
Address
Chariteplatz 1
10117 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data